Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2021 | Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves' Orbitopathy | SHYANG-RONG SHIH ; SHU-LANG LIAO ; Shih, Chih-Wei; YI-HSUAN WEI ; Lu, Ting-Xuan; Chou, Chien-Hsiang; Yen, Er-Yen; YI-CHENG CHANG ; CHIA-CHI LIN ; Chi, Yu-Chiao; WEI-SHIUNG YANG ; FENG-CHIAO TSAI | Ocular immunology and inflammation | 4 | 4 | |
2020 | A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors | Naing A.; Gainor J.F.; Gelderblom H.; Forde P.M.; Butler M.O.; CHIA-CHI LIN ; Sharma S.; Ochoa De Olza M.; Varga A.; Taylor M.; Schellens J.H.M.; Wu H.; Sun H.; Silva A.P.; Faris J.; Mataraza J.; Cameron S.; Bauer T.M. | Journal for ImmunoTherapy of Cancer | 55 | 46 | |
2022 | First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma | Italiano A.; Cassier P.A.; CHIA-CHI LIN ; Alanko T.; Peltola K.J.; Gazzah A.; Shiah H.-S.; Calvo E.; Cervantes A.; Roda D.; Tosi D.; Gao B.; Millward M.; Warburton L.; Tanner M.; Englert S.; Lambert S.; Parikh A.; Afar D.E.; Vosganian G.; Moreno V. | Cancer Immunology, Immunotherapy | 5 | 5 | |
2022 | A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors | Chan, Stephen L; Schuler, Martin; Kang, Yoon-Koo; Yen, Chia-Jui; Edeline, Julien; Choo, Su Pin; CHIA-CHI LIN ; Okusaka, Takuji; Weiss, Karl-Heinz; Macarulla, Teresa; Cattan, Stéphane; Blanc, Jean-Frederic; Lee, Kyung-Hun; Maur, Michela; Pant, Shubham; Kudo, Masatoshi; Assenat, Eric; Zhu, Andrew X; Yau, Thomas; Lim, Ho Yeong; Bruix, Jordi; Geier, Andreas; Guillén-Ponce, Carmen; Fasolo, Angelica; Finn, Richard S; Fan, Jia; Vogel, Arndt; Qin, Shukui; Riester, Markus; Katsanou, Vasiliki; Chaudhari, Monica; Kakizume, Tomoyuki; Gu, Yi; Porta, Diana Graus; Myers, Andrea; Delord, Jean-Pierre | Journal of experimental & clinical cancer research : CR | 20 | | |
2013 | First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Drugs | 15 | 16 | |
2014 | First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial | CHIH-HSIN YANG ; Kang J.H.; Mok T.; Ahn M.-J.; Srimuninnimit V.; CHIA-CHI LIN ; Kim D.-W.; Tsai C.-M.; Barraclough H.; Altug S.; Orlando M.; Park K. | European Journal of Cancer | 41 | 40 | |
2016 | Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study | CHIH-HSIN YANG ; Srimuninnimit V; Ahn M.-J; CHIA-CHI LIN ; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. | Journal of Thoracic Oncology | 22 | 20 | |
2010 | Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. | YU-YUN SHAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Discovery medicine | 13 | 12 | |
2007 | Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; Keng H.-Y.; YU-CHIEH TSAI ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU | Anti-Cancer Drugs | 32 | 29 | |
2008 | Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial | CHIUN HSU ; SUNG-HSIN KUO ; Hu F.-C.; ANN-LII CHENG ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIA-CHI LIN ; Huang T.-C.; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 14 | 11 | |
2001 | Genetic characterization of the rotaviruses associated with a nursery outbreak | Lee C.-N.; CHIA-CHI LIN ; CHUAN-LIANG KAO ; Zao C.-L.; Shih M.-C.; Chen H.-N. | Journal of Medical Virology | 29 | | |
2022 | Immunotherapy in anaplastic thyroid cancer: Case series | SHYANG-RONG SHIH ; Chen, Kuan-Hua; Lin, Kuan-Yu; PAN-CHYR YANG ; KUEN-YUAN CHEN ; CHUN-WEI WANG ; Chun-Nan Chen ; CHIH-FENG LIN ; CHIA-CHI LIN | Journal of the Formosan Medical Association = Taiwan yi zhi | 7 | 6 | |
2013 | The impact of gender on outcomes in patients with metastatic urothelial carcinoma | Haines L.; Bamias A.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.H.; Moshier E.; Sonpavde G.; Godbold J.; Oh W.K.; Galsky M.D. | Clinical Genitourinary Cancer | 20 | 16 | |
2020 | Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer | Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; CHIA-CHI LIN ; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D. | Lung Cancer | 14 | 12 | |
2008 | Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study | FENG-MING HSU ; CHIA-CHI LIN ; JANG-MING LEE ; YIH-LEONG CHANG ; CHIH-HUNG HSU ; YU-CHIEH TSAI ; Lee Y.-C.; CHIA-HSIEN CHENG | Journal of Surgical Oncology | 32 | 29 | |
2019 | Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment | SHAO-LUN LU ; Feng-Ming Hsu ; CHIAO-LING TSAI ; JANG-MING LEE ; PEI-MING HUANG ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YIH-LEONG CHANG ; MIN-SHU HSIEH ; CHIA-HSIEN CHENG | European Journal of Surgical Oncology | 9 | 7 | |
2019 | Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; CHIA-CHI LIN ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 27 | 24 | |
2024 | Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study | Capdevila, Jaume; Krajewska, Jolanta; Hernando, Jorge; Robinson, Bruce; Sherman, Steven I; Jarzab, Barbara; CHIA-CHI LIN ; Vaisman, Fernanda; Hoff, Ana O; Hitre, Erika; Bowles, Daniel W; Williamson, Denise; Levytskyy, Roman; Oliver, Jennifer; Keam, Bhumsuk; Brose, Marcia S | Thyroid : official journal of the American Thyroid Association | | | |
2009 | Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; Feng-Ming Hsu ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU | International Journal of Radiation Oncology Biology Physics | 27 | 22 | |
2020 | An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer | Bible K.C.; Menefee M.E.; CHIA-CHI LIN ; Millward M.J.; Maples W.J.; Goh B.C.; Karlin N.J.; Kane M.A.; Adkins D.R.; Molina J.R.; Donehower R.C.; Lim W.-T.; Flynn P.J.; Richardson R.L.; Traynor A.M.; Rubin J.; Lorusso P.M.; Smallridge R.C.; Burton J.K.; Suman V.J.; Kumar A.; Voss J.S.; Rumilla K.M.; Kipp B.R.; Chintakuntlawar A.V.; Harris P.; Erlichman C. | Thyroid | 15 | 13 | |